Design, synthesis and characterisation of the
2.4. Supporting Information of Chapter II
TEM characterisation confirmed the size of the hydrophobic IONP synthesised by thermal decomposition method.
Figure S2.1. Size characterisation of the magnetite NPs employed in this thesis. (a) Representative TEM
image of the hydrophobic IONPs and (b) the size distribution of more than 200 NPs.
References
1. Thanh, N. T. K. & Green, L. A. W. Functionalisation of nanoparticles for biomedical applications. Nano Today 5, 213–230 (2010). 2. Akbarzadeh, A., Samiei, M. & Davaran, S. Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res. Lett. 7, 144 (2012). 3. Wahajuddin & Arora, S. Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int. J. Nanomedicine 7, 3445–3471 (2012). 4. Kodama, R. . Magnetic nanoparticles. J. Magn. Magn. Mater. 200, 359–372
(1999).
5. Polyak, B. & Friedman, G. Magnetic targeting for site‐specific drug delivery: applications and clinical potential. Expert Opin. Drug Deliv. 6, 53–70 (2009). 6. Wáng, Y. X. J. & Idée, J.‐M. A comprehensive literatures update of clinical
researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging. Quant. Imaging Med. Surg. 7, 88–122 (2017). 7. Salunkhe, A. B. B., Khot, V. M. M. & Pawar, S. H. H. Magnetic Hyperthermia with
Magnetic Nanoparticles: A Status Review. Curr. Top. Med. Chem. 14, 572–594 (2014).
8. Guardia, P., Labarta, A. & Batlle, X. Tuning the Size, the Shape, and the Magnetic Properties of Iron Oxide Nanoparticles. J. Phys. Chem. C 115, 390–396 (2011). 9. Wu, W., He, Q. & Jiang, C. Magnetic iron oxide nanoparticles: Synthesis and
surface functionalization strategies. Nanoscale Res. Lett. 3, 397–415 (2008). 10. Wu, W., Wu, Z., Yu, T., Jiang, C. & Kim, W.‐S. Recent progress on magnetic iron
oxide nanoparticles: synthesis, surface functional strategies and biomedical applications. Sci. Technol. Adv. Mater. 16, 23501 (2015). 11. Patsula, V. et al. Superparamagnetic Fe3O 4 Nanoparticles: Synthesis by Thermal Decomposition of Iron(III) Glucuronate and Application in Magnetic Resonance Imaging. ACS Appl. Mater. Interfaces 8, 7238–7247 (2016). 12. He, X., Zhong, W., Au, C.‐T. & Du, Y. Size dependence of the magnetic properties of Ni nanoparticles prepared by thermal decomposition method. Nanoscale Res. Lett. 8, 446 (2013). 13. Wang, D., Ma, Q. & Yang, P. Synthesis of Fe3O4 nanoparticles with tunable and uniform size through simple thermal decomposition. J. Nanosci. Nanotechnol.
12, 6432–8 (2012).
14. Navaladian, S., Viswanathan, B., Viswanath, R. P. & Varadarajan, T. K. Thermal decomposition as route for silver nanoparticles. Nanoscale Res. Lett. 2, 44–48 (2007).
15. Asuha, S., Zhao, S., Wu, H. Y., Song, L. & Tegus, O. One step synthesis of maghemite nanoparticles by direct thermal decomposition of Fe‐urea complex and their properties. J. Alloys Compd. 472, L23–L25 (2009).
16. Sun, S. et al. Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J. Am.
Chem. Soc. 126, 273–279 (2004).
17. Lattuada, M. & Hatton, T. A. Functionalization of Monodisperse Magnetic Nanoparticles Functionalization of Monodisperse Magnetic Nanoparticles. 23, 2158–2168 (2007).
18. Chen, Z. P. et al. Preparation and characterization of water‐soluble monodisperse magnetic iron oxide nanoparticles via surface double‐exchange with DMSA. Colloids Surfaces A Physicochem. Eng. Asp. 316, 210–216 (2008). 19. Smolensky, E. D., Park, H.‐Y. E., Berquó, T. S. & Pierre, V. C. Surface
functionalization of magnetic iron oxide nanoparticles for MRI applications ‐ effect of anchoring group and ligand exchange protocol. Contrast Media Mol.
Imaging 6, 189–99 (2011).
20. Dubertret, B. In Vivo Imaging of Quantum Dots Encapsulated in Phospholipid Micelles. Science (80‐. ). 298, 1759–1762 (2002).
21. Pellegrino, T. et al. Hydrophobic nanocrystals coated with an amphiphilic polymer shell: A general route to water soluble nanocrystals. Nano Lett. 4, 703– 707 (2004).
22. Geissbuehler, I. et al. Lipid‐coated nanocrystals as multifunctionalized luminescent scaffolds for supramolecular biological assemblies. Angew. Chemie
Int. Ed. 44, 1388–1392 (2005).
23. Jokerst, J. V, Lobovkina, T., Zare, R. N. & Gambhir, S. S. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 6, 715–28 (2011).
24. Alconcel, S. N. S., Baas, A. S. & Maynard, H. D. FDA‐approved poly(ethylene glycol)–protein conjugate drugs. Polym. Chem. 2, 1442 (2011).
25. Stolnik, S. et al. Surface modification of poly(lactide‐co‐glycolide) nanospheres by biodegradable poly(lactide)‐poly(ethylene glycol) copolymers. Pharm. Res.
11, 1800–8 (1994).
26. Lukyanov, A. N. & Torchilin, V. P. Micelles from lipid derivatives of water‐soluble polymers as delivery systems for poorly soluble drugs. Adv. Drug Deliv. Rev. 56, 1273–89 (2004).
27. Lankveld, D. P. et al. Blood clearance and tissue distribution of PEGylated and non‐PEGylated gold nanorods after intravenous administration in rats.
Nanomedicine 6, 339–349 (2011).
28. Perrault, S. D. & Shih, W. M. Virus‐inspired membrane encapsulation of DNA nanostructures to achieve in vivo stability. ACS Nano 8, 5132–5140 (2014).
29. Yang, Q., Moulder K, R., Cohen, M. S., Cai, S. & Forrest, L. M. Cabozantinib Loaded DSPE‐PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation. BAOJ Pharm. Sci. 1, 1–20 (2015). 30. Sperling, R. A. & Parak, W. J. Surface modification, functionalization and
bioconjugation of colloidal inorganic nanoparticles. Philos. Trans. R. Soc. London
A 368, 1333–1383 (2010).
31. Zhao, L. et al. Nanoparticle vaccines. Vaccine 32, 327–337 (2014).
32. Willmann, J. K., van Bruggen, N., Dinkelborg, L. M. & Gambhir, S. S. Molecular imaging in drug development. Nat. Rev. Drug Discov. 7, 591–607 (2008).
33. Rudin, M. & Weissleder, R. Molecular imaging in drug discovery and development. Nat. Rev. Drug Discov. 2, 123–31 (2003).
34. Lee, I. H. et al. Imageable antigen‐presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. Angew. Chemie Int. Ed. 51, 8800–8805 (2012).
35. Huang, H.‐C. et al. Formulation of novel lipid‐coated magnetic nanoparticles as the probe for in vivo imaging. J. Biomed. Sci. 16, 86 (2009).
36. Pysz, M. A., Gambhir, S. S. & Willmann, Jürgen K., M. D. Molecular Imaging: Current Status and Emerging Strategies. Clin. Radiol. 65, 500–516 (2010).
37. Gibson, N. et al. Radiolabelling of engineered nanoparticles for in vitro and in vivo tracing applications using cyclotron accelerators. Arch. Toxicol. 85, 751–773 (2011).
38. Cydzik, I. et al. A novel method for synthesis of 56Co‐radiolabelled silica nanoparticles. J. Nanoparticle Res. 14, 1185–1193 (2012).
39. Torres Martin de Rosales, R. et al. Synthesis of 64Cu(II)‐ bis(dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: in vivo evaluation as dual‐modality PET‐MRI agent. Angew. Chemie Int. Ed. 50, 5509–13 (2011).
40. Ogawa, K., Mukai, T., Inoue, Y., Ono, M. & Saji, H. Development of a novel 99mTc‐chelate‐conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J. Nucl. Med. 47, 2042–7 (2006).
41. Torres Martin de Rosales, R. et al. (99m)Tc‐bisphosphonate‐iron oxide
nanoparticle conjugates for dual‐modality biomedical imaging. Bioconjug. Chem.
22, 455–65 (2011).
42. Lewin, M. et al. Tat peptide‐derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18, 410–4 (2000). 43. Jarrett, B. R., Gustafsson, B., Kukis, D. L. & Louie, A. Y. Synthesis of 64Cu‐labeled
magnetic nanoparticles for multimodal imaging. Bioconjug. Chem. 19, 1496–504 (2008).
44. Lee, H.‐Y. et al. PET/MRI dual‐modality tumor imaging using arginine‐glycine‐ aspartic (RGD)‐conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med.
49, 1371–9 (2008).
45. Glaus, C., Rossin, R., Welch, M. J. & Bao, G. In vivo evaluation of (64)Cu‐labeled magnetic nanoparticles as a dual‐modality PET/MR imaging agent. Bioconjug.
Chem. 21, 715–22 (2010).
46. Patel, D. et al. The cell labeling efficacy, cytotoxicity and relaxivity of copper‐ activated MRI/PET imaging contrast agents. Biomaterials 32, 1167–76 (2011). 47. Boros, E., Bowen, A. M., Josephson, L., Vasdev, N. & Holland, J. P. Chelate‐free
metal ion binding and heat‐induced radiolabeling of iron oxide nanoparticles.
Chem. Sci. 6, 225–236 (2014).
48. Chen, F. et al. Chelator‐free synthesis of a dual‐modality PET/MRI agent. Angew.
Chemie Int. Ed. 52, 13319–23 (2013).
49. Goel, S., Chen, F., Ehlerding, E. B. & Cai, W. Intrinsically radiolabeled nanoparticles: an emerging paradigm. Small 10, 3825–30 (2014).
50. Chakravarty, R. et al. Intrinsically germanium‐69‐labeled iron oxide nanoparticles: synthesis and in‐vivo dual‐modality PET/MR imaging. Adv. Mater.
26, 5119–23 (2014).
51. Jauregui‐osoro, M. et al. Biocompatible inorganic nanoparticles for [18F]‐ fluoride binding with applications in PET imaging. Dalt. Trans. 40, 6196–6205 (2011). 52. Gomez Blanco, N. et al. Iron oxide‐filled micelles as ligands for fac‐[M(CO)3]+ (M = (99m)Tc, Re). Chem. Commun. 48, 4211–3 (2012). 53. Cobaleda‐siles, M. et al. An Iron Oxide Nanocarrier for dsRNA to Target Lymph Nodes and Strongly Activate Cells of the Immune System. Small 10, 5054–5067 (2014).
54. Carion, O., Mahler, B., Pons, T. & Dubertret, B. Synthesis, encapsulation, purification and coupling of single quantum dots in phospholipid micelles for their use in cellular and in vivo imaging. Nat. Protoc. 2, 2383–2390 (2007). 55. Krieg, A. M. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 22,
77–89 (2012).
56. Meng, W., Yamazaki, T., Nishida, Y. & Hanagata, N. Nuclease‐resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll‐ like receptor 9 agonists. BMC Biotechnol. 11, 88 (2011).
57. Watanabe, J., Miyazaki, Y., Zimmerman, G. a., Albertine, K. H. & McIntyre, T. M. Endotoxin Contamination of Ovalbumin Suppresses Murine Immunologic Responses and Development of Airway Hyper‐reactivity. J. Biol. Chem. 278, 42361–8 (2003).
58. Hwang, D. W. et al. A nucleolin‐targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J. Nucl. Med. 51, 98–105 (2010). 59. Zambre, A. et al. Evaluation of tumor targeting efficacy of 67Ga‐labeled
bombesin peptide functionalized gold nanoparticle in mice model. J. Nucl. Med.
55, 1386‐ (2014).
60. Xing, Y., Zhao, J., Conti, P. S. & Chen, K. Radiolabeled nanoparticles for multimodality tumor imaging. Theranostics 4, 290–306 (2014).
61. Shannon, R. D. Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenides. Acta Crystallogr. Sect. A 32, 751–767 (1976).
62. Bernstein, L. R. Mechanisms of therapeutic activity for gallium. Pharmacol. Rev.
50, 665–82 (1998).
63. Sun, H., Li, H. & Sadler, P. J. Transferrin as a Metal Ion Mediator. Chem. Rev. 99, 2817–2842 (1999).
64. Kaneko, Y., Thoendel, M., Olakanmi, O., Britigan, B. E. & Singh, P. K. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J. Clin. Invest. 117, 877–88 (2007). 65. Maldonado, C. R. et al. QD‐filled micelles which combine SPECT and optical
imaging with light‐induced activation of a platinum(IV) prodrug for anticancer applications. Chem. Commun. 49, 3985–7 (2013).
66. Hu, H. et al. PET and NIR optical imaging using self‐illuminating (64)Cu‐doped chelator‐free gold nanoclusters. Biomaterials 35, 9868–76 (2014).
67. Berry, D. J. et al. Efficient bifunctional gallium‐68 chelators for positron emission tomography: tris(hydroxypyridinone) ligands. Chem. Commun. 47, 7068–70 (2011).